Outset Medical Announced a KidneyX Award Winner by U.S. Department of Health and Human Services and the American Society of Nephrology

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that a project featuring the Tablo™ Hemodialysis System has been selected as a winner of the KidneyX Redesign Dialysis Competition. Outset’s winning concept seeks to couple data from Tablo’s unique set of sensors and automation capabilities with physiologic data from the patient to deliver personalized dialysis treatments, ultimately improving outcomes for patients.

The KidneyX Redesign Dialysis Competition is a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease, a space that has been historically underfunded despite a growing patient population and poor patient outcomes, including high mortality and low quality of life. These sub-optimal outcomes are due in part to dialysis treatment decisions driven by incomplete, imprecise physiologic measurements and a one-size-fits-all approach to treatment planning. Tablo has a proprietary suite of sensors and data sets that can allow it to merge data from the machine and the patient in order to automatically adjust treatment parameters and customize therapy to an individual patient’s needs, all without interrupting clinic workflow.

Outset is one of 15 winners selected for innovative solutions that can help address the growing dialysis population. “Dialysis technology has changed little in 30 years and continues to rely on a cookie cutter approach to treating patients. Other disease areas such as cancer, heart failure and diabetes have rapidly moved towards delivering more personalized treatments based on the underlying physiology of the patient. In dialysis, we have intimate contact with the same patient’s blood for over 600 hours a year while inducing significant, controlled physical and chemical changes. We need to use these data to tailor our approach and deliver a better patient experience and improved clinical outcomes,” said Michael Aragon, M.D., Outset Medical’s Chief Medical Officer.

Tablo was designed to transform the large, but stagnant, dialysis landscape. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of different use environments. Tablo was designed to look and feel like an intuitive consumer product making it accessible to a wide range of users. Wireless data, sensor-based automation and an animated touchscreen make Tablo easy to learn and easy to use for healthcare professionals and patients alike.

“We are very appreciative of the recognition and the opportunity to partner with the KidneyX program to help bring more innovation to the renal space,” said Leslie Trigg, Chief Executive Officer at Outset Medical. “While we are proud of our technology development, we are just getting started. The opportunity to transform dialysis care through software, sensors and predictive data analytics is vast, and achievable.”

In addition to the KidneyX Award, Outset’s Tablo System was also recently recognized with a Gold Edison Award in the medical patient experience category. The Edison Awards honor game-changing innovations at the forefront of new product and service development, marketing and human-centered design. Nominees were judged by a panel of more than 3,000 leading business executives including past award winners, academics and leaders in the fields of product development, design, engineering, science and medicine. Tablo received the top prize in its category, the Gold Award.

About Outset Medical

Silicon Valley-based Outset Medical is dedicated to delivering patient-centered dialysis through service model and technology innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is CE-marked and FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial exploring the use of Tablo for home dialysis. For more information, visit www.outsetmedical.com and follow us on Twitter at @OutsetMedical.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005751/en/